Publications found:
164,030
Sort by:
Acorda Therapeutics - Pipeline and Label Expansion of AMPYRA- Drivers of Growth
US$ 140.00
Stable sales from marketed products, maturing pipeline and focus on targeting unmet needs in CNS diseases- Acorda (ACOR) has not disappointed its investors ... detail, please read our report released on June 06, 2013, titled, “Acorda Therapeutics - Pipeline and Label Expansion of AMPYRA- Drivers of Growth”.
June 2013
3 pages
MorphoSys - MOR103 – Partnering is Just the Beginning of a New Phase of Growth
US$ 140.00
Licensing of un-partnered early programs and the clinical data of its maturing therapeutic antibody pipeline are future drivers of Morphosys (MOR). After selling ... detail, please read our report released on June 05, 2013, titled, “MorphoSys - MOR103 – Partnering is Just the Beginning of a New Phase of Growth”.
June 2013
5 pages
ASCO ‘13 - Promise of Novel Targets/Technologies to Unfold At ASCO 2013
US$ 140.00
... / BiTE) for Hematological Malignancies and Solid tumors will be highlighted at ASCO. These include Amgen’s T-VEC (PhIII), Blinatumomab (PhII/III); Gilead ... detail, please read our report released on May 29, 2013, titled, “ASCO ‘13 - Promise of Novel Targets/Technologies to Unfold ...
May 2013
12 pages
Annual Strategy Dossier - 2013 - World's 6 Leading Agriculture Equipment Manufacturers - Key Strategies, Plans, SWOT, Trends & Strategic Outlook - John Deere, CNH, AGCO, CLAAS, SAME Deutz-Fahr, Kubota
US$ 1,295.00
... Growth Wave 3. Analysis of CLAAS Group’s Technological Backbone & International Diversification Strategy 4. Analysis of SAME Deutz-Fahr’s plans to make India its Global ... on the Business & Strategic Outlook for all key players for 2013 Gaining access to Key Industry as well as Market Trends, Insights & Growth ...
May 2013
83 pages
CompetitiveWatch: Sensient
US$ 1,960.00
This strategic assessment of Sensient, one of the world’s leading flavor and fragrance companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report from Venture Planning Group presents a ...
May 2013
45 pages
CompetitiveWatch: Soda Aromatic
US$ 1,960.00
This strategic assessment of Soda Aromatic, one of the world’s leading flavor and fragrance companies, provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report from Venture Planning Group presents a ...
May 2013
16 pages
VERTEX PHARMA - Dependence on Success of its CF Pipeline = Risk
US$ 140.00
Vertex Pharma’s (VRTX) stock has moved up ~30% in this year mostly based on the ... detail, please read our report released on 9th March, 2013 on Vertex titled “Dependence on Success of its CF Pipeline = Risk!” Companies mentioned Vertex Pharma
April 2013
4 pages
RIGEL - SyK Inhibition Not Good Enough - Limited Market Potential!
US$ 140.00
RIGL/AZN’s Fostamatinib (FosD, syk inhibitor, PhIII) has again disappointed by not demonstrating better or at par efficacy with approved or competing RA drugs. ... , please read our report released on April 5, 2013, titled, “SyK Inhibition Not Good Enough - Limited Market Potential!” Companies mentioned Rigel
April 2013
5 pages